dc.contributor.author | Kiddle, SJ | |
dc.contributor.author | Thambisetty, M | |
dc.contributor.author | Simmons, A | |
dc.contributor.author | Riddoch-Contreras, J | |
dc.contributor.author | Hye, A | |
dc.contributor.author | Westman, E | |
dc.contributor.author | Pike, I | |
dc.contributor.author | Ward, M | |
dc.contributor.author | Johnston, C | |
dc.contributor.author | Lupton, MK | |
dc.contributor.author | Lunnon, Katie | |
dc.contributor.author | Soininen, H | |
dc.contributor.author | Kloszewska, I | |
dc.contributor.author | Tsolaki, M | |
dc.contributor.author | Vellas, B | |
dc.contributor.author | Mecocci, P | |
dc.contributor.author | Lovestone, Simon | |
dc.contributor.author | Newhouse, S | |
dc.contributor.author | Dobson, R | |
dc.contributor.author | Alzheimers Disease Neuroimaging Initiative | |
dc.date.accessioned | 2016-02-11T14:00:58Z | |
dc.date.issued | 2012-09-24 | |
dc.description.abstract | Changes in brain amyloid burden have been shown to relate to Alzheimer's disease pathology, and are believed to precede the development of cognitive decline. There is thus a need for inexpensive and non-invasive screening methods that are able to accurately estimate brain amyloid burden as a marker of Alzheimer's disease. One potential method would involve using demographic information and measurements on plasma samples to establish biomarkers of brain amyloid burden; in this study data from the Alzheimer's Disease Neuroimaging Initiative was used to explore this possibility. Sixteen of the analytes on the Rules Based Medicine Human Discovery Multi-Analyte Profile 1.0 panel were found to associate with [(11)C]-PiB PET measurements. Some of these markers of brain amyloid burden were also found to associate with other AD related phenotypes. Thirteen of these markers of brain amyloid burden--c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolipoprotein E and immunoglobulin E--were used along with co-variates in multiple linear regression, and were shown by cross-validation to explain >30% of the variance of brain amyloid burden. When a threshold was used to classify subjects as PiB positive, the regression model was found to predict actual PiB positive individuals with a sensitivity of 0.918 and a specificity of 0.545. The number of APOE [Symbol: see text] 4 alleles and plasma apolipoprotein E level were found to contribute most to this model, and the relationship between these variables and brain amyloid burden was explored. | en_GB |
dc.description.sponsorship | Alzheimer's Disease Neuroimaging Initiative (ADNI) | en_GB |
dc.description.sponsorship | Canadian Institutes of Health Research | en_GB |
dc.description.sponsorship | Foundation for the National Institutes of Health | en_GB |
dc.description.sponsorship | National Institutes of Health | en_GB |
dc.description.sponsorship | InnoMed, European Union of the Sixth Framework program | en_GB |
dc.description.sponsorship | National Institutes for Health Research Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service Foundation Trust | en_GB |
dc.description.sponsorship | Institute of Psychiatry, King's College London | en_GB |
dc.identifier.citation | Vol. 7, Iss. 9, pp. e44260 - | en_GB |
dc.identifier.doi | 10.1371/journal.pone.0044260 | |
dc.identifier.grantnumber | U01 AG024904 | en_GB |
dc.identifier.grantnumber | P30 AG010129 | en_GB |
dc.identifier.grantnumber | K01 AG030514 | en_GB |
dc.identifier.grantnumber | FP6-2004-LIFESCIHEALTH-5 | en_GB |
dc.identifier.other | PONE-D-12-10525 | |
dc.identifier.uri | http://hdl.handle.net/10871/19723 | |
dc.language.iso | en | en_GB |
dc.publisher | Public Library of Science | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/23028511 | en_GB |
dc.relation.url | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0044260 | en_GB |
dc.rights | This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. | en_GB |
dc.subject | Aged | en_GB |
dc.subject | Aged, 80 and over | en_GB |
dc.subject | Alzheimer Disease | en_GB |
dc.subject | Amyloid beta-Peptides | en_GB |
dc.subject | Aniline Compounds | en_GB |
dc.subject | Apolipoproteins E | en_GB |
dc.subject | Biomarkers | en_GB |
dc.subject | Brain | en_GB |
dc.subject | Cluster Analysis | en_GB |
dc.subject | Female | en_GB |
dc.subject | Genotype | en_GB |
dc.subject | Humans | en_GB |
dc.subject | Male | en_GB |
dc.subject | Metabolome | en_GB |
dc.subject | Metabolomics | en_GB |
dc.subject | Middle Aged | en_GB |
dc.subject | Positron-Emission Tomography | en_GB |
dc.subject | Prognosis | en_GB |
dc.subject | Reproducibility of Results | en_GB |
dc.subject | Thiazoles | en_GB |
dc.title | Plasma based markers of [11C] PiB-PET brain amyloid burden. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2016-02-11T14:00:58Z | |
dc.identifier.issn | 1932-6203 | |
exeter.place-of-publication | United States | |
dc.description | Published | en_GB |
dc.description | Journal Article | en_GB |
dc.description | Research Support, N.I.H., Extramural | en_GB |
dc.description | Research Support, Non-U.S. Gov't | en_GB |
dc.identifier.journal | PLoS One | en_GB |